Strathprints logo
Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug

Smith, K.D. and Paterson, S. (2005) Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug. Haematologica, 90. pp. 9-10. ISSN 0390-6078

[img] Other
307239.mht - Draft Version

Download (281kB)

Abstract

Imatinib mesylate (Glivec®, Novartis Pharma) is a highlyefficacious tyrosine kinase inhibitor, designed for treatment of chronic myeloid leukaemia (CML), by virtue of its ability to inhibit the oncogenic signalling of the BCR-ABL protein believed to be the causative abnormality of the disease. However, resistance is observed in a subset of CML patients, which could be due to mutations in BCR-ABL that prohibit binding of imatinib or overexpression of the BCR-ABL gene (Paterson et al, 2003). Alternatively, circulating serum proteins have been proposed as an alternative mechanism that reduces imatinib efficacy through non specific binding to the drug. In particular, it has been suggested that the protein a-1-acid glycoprotein (AGP) can bind to imatinib in the plasma and hence decrease the free, and therefore active, concentration of the drug (Gambacorti-Passerini et al, 2000).

Item type: Article
ID code: 10975
Keywords: pharmaceutical, materia medica, Pharmacy and materia medica, Hematology
Subjects: Medicine > Pharmacy and materia medica
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Unknown Department
Depositing user: Strathprints Administrator
Date Deposited: 27 Sep 2011 14:19
Last modified: 21 May 2015 10:22
URI: http://strathprints.strath.ac.uk/id/eprint/10975

Actions (login required)

View Item View Item